Futurity October 10, 2024
A “significant breakthrough” in HIV prevention could be on the horizon, according to the World Health Organization.
Results of an interim analysis from a Phase 3 clinical trial sponsored by Gilead Sciences, Inc., showed that lenacapavir, a twice-yearly injectable drug, is a highly promising tool for thwarting new HIV infections.
Here, Onyema Ogbuagu, associate professor of medicine (AIDS) and of pharmacology at Yale School of Medicine and the study’s principal investigator, about the trial, named PURPOSE 2, and the future of lenacapavir:
Q What is lenacapavir and how does it work to prevent HIV?
A Lenacapavir is a first-in-class HIV drug, which means that it has a mechanism of action that has not...
Today's Sponsors
Today's Sponsor